There has been some reference to the Indian generic version (I think i was also discussed by 51 Cap a while ago) and their analysis felt that the same bio marks (via certain performance graph of the molecules) were NOT exact to iPPS, meaning that for them to be recognised and given the go ahead in FDA certified circles/jurisdictions, they may be subject to their own trials, ie a long process. In addition, there was also some discussion of them not meeting the strict quality and consistency controls that were imposed by FDA checks.
...as Hercules often says....Next!
DYOR
Fiftyone Capital Update, page-17
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.005(2.56%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.0¢ | 20.0¢ | $129.1K | 636.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 39624 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 60008 | 3 |
View Market Depth
| Last trade - 12.53pm 10/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |